Colette Roche

Colette Roche

Auto-generated profile, based on publicly available information

Colette Roche

INSERM U1052/CNRS UMR5286/University of Lyon, Cancer Research Center of Lyon, 69622 Lyon, France

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
MJMarjorie Jenny
Marjorie Jenny
CUCéline Uhl
Céline Uhl
CRColette Roche
Colette Roche
IDIsabelle Duluc
Isabelle Duluc
VGValérie Guillermin
Valérie Guillermin
GGGérard Gradwohl
Gérard Gradwohl
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 October 2010 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
ARAmelie Rezza
Amelie Rezza
SSSeham Skah
Seham Skah
CRColette Roche
Colette Roche
JNJulien Nadjar
Julien Nadjar
JSJacques Samarut
Jacques Samarut
MPMichelina Plateroti
Michelina Plateroti
The RNA-binding protein Musashi-1 (Msi1) has been proposed as a marker of intestinal epithelial stem cells. These cells are responsible for the continuous renewal of the intestinal epithelium. Although the function of Msi1 has been studied in several organs from different species and in mammalian cell lines, its function and molecular regulation in mouse intestinal epithelium progenitor cells are still undefined. We describe here that, in these cells, the expression of Msi1 is regulated by the canonical Wnt pathway, through a mechanism involving a functional Tcf/Lef binding site on its promoter. An in vitro study in intestinal epithelium primary cultures showed that Msi1 overexpression promotes progenitor proliferation and activates Wnt and Notch pathways. Moreover, Msi1-overexpressing cells exhibit tumorigenic properties in xenograft experiments. These data point to a positive feedback loop between Msi1 and Wnt in intestinal epithelial progenitors. They also suggest that Msi1 has oncogenic properties in these cells, probably through induction of both the Wnt and Notch pathways.

13 April 2010 in Neuroendocrinology
Verified
Journal Article
Closed access
KVKarine Villaume
Karine Villaume
MBMartine Blanc
Martine Blanc
GGGéraldine Gouysse
Géraldine Gouysse
TWThomas Walter
Thomas Walter
CCChristophe Couderc
Christophe Couderc
JSJean-Yves Scoazec
Jean-Yves Scoazec
Gastroenteropancreatic (GEP) endocrine tumors are hypervascular tumors able to synthesize and secrete high amounts of VEGF. We aimed to study the regulation of VEGF production in GEP endocrine tumors and to test whether some of the drugs currently used in their treatment, such as so- matostatin analogues and mTOR inhibitors, may interfere with VEGF secretion. We therefore analyzed the effects of the somatostatin analogue octreotide, the mTOR inhibitor rapamycin, the PI3K inhibitor LY294002, the MEK1 inhibitor PD98059 and the p38 inhibitor SB203850 on VEGF secretion, assessed by ELISA and Western blotting, in three murine endocrine cell lines, STC-1, INS-r3 and INS-r9. Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only. We detected no effect of PD98059 whereas SB203850 significantly inhibited VEGF secretion in INS-r3 and INS-r9 cells only. By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1α under octreotide, rapamycin and LY294002. For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway. In addition to its well-known anti-secretory effects, octreotide may also act through the inhibition of the PI3K/Akt pathway, as suggested by the decrease in Akt phosphorylation detected in all three cell lines. In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects.

1 June 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CRChristelle Ratineau
Christelle Ratineau
CBChristine Bernard
Christine Bernard
GPGilles Poncet
Gilles Poncet
MBMartine Blanc
Martine Blanc
CJClaire Josso
Claire Josso
CRColette Roche
Colette Roche
Menin, the product of the tumor suppressor gene MEN1, is widely expressed in mammalian endocrine and non-endocrine tissues, including intestine. Its known abundant expression in several types of cells with high proliferative capacity led us to investigate the physiological function of the protein menin in intestinal epithelium, one of the most rapidly growing epithelia. Here we showed that the Men1 gene is mainly expressed in the crypt compartment of the proximal small intestine and that its expression was increased during fasting in vivo, both suggesting a role of menin in the control of cell growth. Indeed, specific reduction of menin expression by transfected antisense cDNA in the rat duodenal crypt-like cell line, IEC-17, increased cell proliferation. The latter is correlated to a loss of cell-cycle arrest in G1 phase by resting cells and an overexpression of cyclin D1 and cyclin-dependent kinase (Cdk)-4. Furthermore, these cells lost the inhibition of proliferation induced by transforming growth factor-β1, associated with a decrease of transforming growth factor-β type II receptor expression. As a result of deregulated proliferation, antisense menin transfected IEC-17 cells became tumorigenic as shown in vitro as well as in vivo in immunosuppressed animals. These results indicate that menin contributes to proliferation control in intestinal epithelial cells. The present study reveals an unknown physiological function for menin in intestine that may be important in the regulation of epithelial homeostasis.

1 November 2008 in Gastroenterology
Verified
Journal Article
Closed access
WBWissam Bazzi
Wissam Bazzi
MRMaud Renon
Maud Renon
CVCécile Vercherat
Cécile Vercherat
ZHZeinab Hamze
Zeinab Hamze
ALAnnie Lacheretz–Bernigaud
Annie Lacheretz–Bernigaud
MCMartine Cordier–Bussat
Martine Cordier–Bussat

23 January 2013 in Neuroendocrinology
Verified
Journal Article
Closed access
JBJulien Bollard
Julien Bollard
CCChristophe Couderc
Christophe Couderc
MBMartine Blanc
Martine Blanc
GPGilles Poncet
Gilles Poncet
FLFlorian Lepinasse
Florian Lepinasse
CRColette Roche
Colette Roche
Background/Aims: While the range of therapeutic options for well-differentiated gastroenteropancreatic neuroendocrine tumors has recently increased with the emergence of targeted therapies, such as mTOR inhibitors, there is no recent progress in the treatment of poorly differentiated neuroendocrine carcinomas (PDNECs). Since PDNECs have been shown to strongly express mTOR pathway components, the aim of the present study was to assess the antitumor effect of the mTOR inhibitor everolimus in preclinical models of PDNECs. Methods: The expression of mTOR pathway components and their response to everolimus were assessed in two neuroendocrine cell lines: STC-1 and GluTag. A xenograft model of intrahepatic dissemination in the nude mouse, based on the intrasplenic injection of either STC-1 and GluTag tumor cells, was used. Animals were started on everolimus treatment 3 days after injection. The effects of treatment on tumor growth, proliferative capacities, apoptosis and in situ expression of mTOR pathway components were assessed. Results: The expression of mTOR pathway components was comparable in STC-1 and GluTag cells and in human PDNECs and could be inhibited in vitro by everolimus. In vivo, the tumor volume of STC-1 and GluTag xenografts was significantly reduced in treated animals (6.05 ± 1.84% as compared to 21.76 ± 3.88% in controls). Everolimus treatment also induced a significant decrease in Ki67 index and in the phosphorylation levels of the two major effectors of mTOR, p70S6K and 4E-BP1. Conclusion: Our experimental data suggest that mTOR inhibition could be considered a therapeutic option for high-grade gastroenteropancreatic neuroendocrine tumors.